![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZGc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--bfb850ca077ddfe09bb96620ae12f18c6354e5a1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Novira.png)
Novira Therapeutics
Novira is an antiviral drug discovery company focused on the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.
Partner
Tim ShannonInvestment
Series A
Novira is an antiviral drug discovery company focused on the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.
Series A